PL-3994
Also known as: Cys(Et)-c[Lys-Asp-Arg-Ile-c(Cys-Phe-Gly)], PL-3994, PL3994
Source PL-3994 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
PL-3994 is a synthetic peptide V2‑receptor agonist being investigated as an ophthalmic solution for the treatment of dry eye disease by increasing tear production.
Mechanism of Action
Selective V2 vasopressin receptor agonist; stimulates aqueous tear secretion via aquaporin insertion in ocular surface epithelia.
Routes of Administration
Goals & Uses
- Dry eye diseaseOphthalmologyModerate
- Bronchodilation / asthmaPulmonaryLow
- Dry mouth (xerostomia)Salivary Gland DisorderLow
- Acute decompensated heart failure treatmentCardiovascularModerate
- Blood pressure reduction / hypertensionCardiovascularModerate
- Diuresis / natriuresisRenalModerate
Contraindications
- Severe renal impairmentOrganModerateKidney function concerns
- Known hypersensitivity to PL-3994 or componentsImmunologicHigh
- Hypotension or cardiogenic shockCardiovascularHigh
- HyponatremiaElectrolyte/MetabolicModerate
Adverse Effects
- Injection site reactionsLocalUncommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- Ocular irritationLocalCommon
- HypotensionCardiovascularCommonLow blood pressure
- FlushingVascularUncommonWarmth and redness of the skin
- Blurred visionVisualUncommon
Drug Interactions
- Antihypertensive agentsModerate
- DiureticsModerateMay worsen dehydration or electrolyte imbalance
- Phosphodiesterase-5 inhibitors (e.g., sildenafil)High
- DesmopressinModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Elderly patientsAgeRelative
- Pregnant womenReproductiveRelative
- Children <12 yearsAgeRelative
Regulatory Status
- European UnionInvestigationalNo EMA marketing authorization.
- United StatesInvestigationalPhase II clinical trials ongoing; not FDA‑approved.
- United KingdomInvestigationalUnder clinical investigation; not licensed.
No approved indication in any major jurisdiction. Investigated in Phase I/II clinical trials. Developed by Palatin Technologies.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is PL-3994?
PL-3994 is a synthetic peptide V2‑receptor agonist being investigated as an ophthalmic solution for the treatment of dry eye disease by increasing tear production.
What is PL-3994 used for?
PL-3994 is educationally associated with: Dry eye disease, Bronchodilation / asthma, Dry mouth (xerostomia), Acute decompensated heart failure treatment, Blood pressure reduction / hypertension, Diuresis / natriuresis. Educational only — not medical advice.
How is PL-3994 administered?
Recorded routes of administration: Intravenous, Subcutaneous, Topical Ophthalmic.
What are the potential side effects of PL-3994?
Reported adverse effects include: Injection site reactions, Headache, Ocular irritation, Hypotension, Flushing, Blurred vision. This list is not exhaustive — consult a qualified clinician.
Who should avoid PL-3994?
Recorded contraindications: Severe renal impairment, Known hypersensitivity to PL-3994 or components, Hypotension or cardiogenic shock, Hyponatremia. Consult a qualified clinician before use.